Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Authors
Keywords
-
Journal
SCHIZOPHRENIA BULLETIN
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-01-05
DOI
10.1093/schbul/sbac001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
- (2021) Masaomi Iyo et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
- (2020) Christoph U. Correll et al. JAMA Psychiatry
- Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
- (2020) Christoph U. Correll et al. npj Schizophrenia
- Lurasidone in the treatment of schizophrenia: Results of a double‐blind, placebo‐controlled trial in Asian patients
- (2019) Teruhiko Higuchi et al. Asia-Pacific Psychiatry
- Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats
- (2019) Gavin P. Reynolds et al. Clinical Psychopharmacology and Neuroscience
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
- (2019) Stephen J. Kaar et al. NEUROPHARMACOLOGY
- Effects of long-term antipsychotics treatment on body weight: A population-based cohort study
- (2019) Juan Carlos Bazo-Alvarez et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia
- (2019) Stefan Leucht et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study
- (2018) Jun Ishigooka et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- One-stage dose–response meta-analysis for aggregated data
- (2018) Alessio Crippa et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
- (2018) Zheng Tong et al. BMC Medical Research Methodology
- How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis
- (2017) Yikang Zhu et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
- (2017) Spyridon Siafis et al. Current Neuropharmacology
- Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method
- (2017) Philipp H. Rothe et al. SCHIZOPHRENIA RESEARCH
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- Dose-response meta-analysis of differences in means
- (2016) Alessio Crippa et al. BMC Medical Research Methodology
- Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
- (2016) Ronald Landbloom et al. CNS SPECTRUMS
- Cariprazine in the treatment of schizophrenia
- (2016) Suresh Durgam et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia
- (2016) Antony Loebel et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia
- (2016) Azmi F. Nasser et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
- (2016) Toshihiko Kinoshita et al. PSYCHOPHARMACOLOGY
- Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1.
- (2016) Stefan Leucht et al. SCHIZOPHRENIA BULLETIN
- AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study
- (2016) Robert E. Litman et al. SCHIZOPHRENIA RESEARCH
- Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
- (2016) Christoph U. Correll et al. SCHIZOPHRENIA RESEARCH
- Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment
- (2016) Mette Ø. Nielsen et al. JAMA Psychiatry
- Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
- (2016) Myrto T. Samara et al. JAMA Psychiatry
- Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
- (2015) Christoph U. Correll et al. AMERICAN JOURNAL OF PSYCHIATRY
- Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) Suresh Durgam et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
- (2015) Herbert Y. Meltzer et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
- (2015) Stefan Leucht et al. SCHIZOPHRENIA BULLETIN
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Weight gain and antipsychotics: a drug safety review
- (2014) Richard Musil et al. Expert Opinion On Drug Safety
- Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia
- (2014) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia
- (2014) Robert E. Litman et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia
- (2014) Joan H.Q. Shen et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
- (2014) Maarten Bak et al. PLoS One
- Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
- (2014) S. Leucht et al. SCHIZOPHRENIA BULLETIN
- A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia
- (2014) H.Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
- (2014) Marc Cantillon SCHIZOPHRENIA RESEARCH
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
- (2014) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms
- (2013) Donald C. Goff et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
- (2013) Henry A. Nasrallah et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
- (2013) Antony Loebel et al. SCHIZOPHRENIA RESEARCH
- Imputation of response rates from means and standard deviations in schizophrenia
- (2013) Myrto T. Samara et al. SCHIZOPHRENIA RESEARCH
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
- (2012) Masaaki Ogasa et al. PSYCHOPHARMACOLOGY
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
- (2011) Herbert Y. Meltzer et al. AMERICAN JOURNAL OF PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of High-Dose Quetiapine in Patients With Persistent Symptoms of Schizophrenia or Schizoaffective Disorder
- (2011) William G. Honer et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Parallel-Group, Fixed-Dose, Clinical Trial of Quetiapine at 600 Versus 1200 mg/d for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder
- (2011) Jean-Pierre Lindenmayer et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Management of antipsychotic-related weight gain
- (2010) Lawrence Maayan et al. Expert Review of Neurotherapeutics
- Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
- (2010) Srihari Gopal et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder
- (2010) Carla M. Canuso et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia
- (2010) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia
- (2010) Gahan J. Pandina et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
- (2010) Henry A Nasrallah et al. NEUROPSYCHOPHARMACOLOGY
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
- (2009) Mario Álvarez-Jiménez et al. CNS DRUGS
- Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
- (2009) Michelle Kramer et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia
- (2009) John Lauriello et al. JOURNAL OF CLINICAL PSYCHIATRY
- Lurasidone in the Treatment of Acute Schizophrenia
- (2009) Mitsutaka Nakamura et al. JOURNAL OF CLINICAL PSYCHIATRY
- Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
- (2009) Viktoria Simon et al. JOURNAL OF CLINICAL PSYCHIATRY
- Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder
- (2009) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
- (2008) Stefan Leucht et al. AMERICAN JOURNAL OF PSYCHIATRY
- Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia
- (2008) Andrew J. Cutler et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Efficacy of Iloperidone in the Treatment of Schizophrenia
- (2008) Steven G. Potkin et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
- (2008) S Leucht et al. MOLECULAR PSYCHIATRY
- Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
- (2008) Daniel E. Casey et al. PSYCHOPHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started